Pediatric Gastroenterology Unit, Centro Materno-Infantil do Norte, Centro Hospitalar do Porto, Oporto, Portugal.
Helicobacter. 2018 Oct;23(5):e12528. doi: 10.1111/hel.12528. Epub 2018 Aug 9.
The increasing prevalence of Helicobacter pylori (H. pylori) antimicrobial resistance, primarily for clarithromycin decreases the success of treatment. The aim of this study is to determine the local pattern of first-line antimicrobials resistance and the eradication rate.
Prospective cohort study of H. pylori infected patients (positive histological or cultural exams) treated at Centro Materno-Infantil do Norte from January of 2013 to October of 2017. Susceptibility to 4 antibiotics: amoxicilin, metronidazole, clarithromycin, and levofloxacin were analyzed by E-test (phenotypic resistance). The E-test was chosen because it is simple and cost-effective for routine susceptibility testing. Point mutations that confer clarithromycin resistance were surveyed (genotypic resistance). Eradication of H. pylori infection was defined by a negative urea breath test or fecal antigen 6-8 weeks after the end of treatment.
Of a total of 74 H. pylori infected patients, 16 were excluded because they had previous H. pylori treatment or severe systemic disease. Median age of infection cases was 15 years (3-17 years). Eradication regimen used in all patients combined the use of 3 antibiotics (amoxicillin and metronidazole or clarithromycin) and proton pump inibhitor for 14 days and was tailored according antimicrobial susceptibility. 79.5% of the patients completed the treatment. The resistance rate for metronidazole and clarithromycin was 3.3% and 23.3%, respectively. There was no resistance for amoxicilin and levofloxacin. The rate of genotypic resistance to clarithromycin was 37.2%. The eradication rate was 97.8%.
The authors found a high resistance rate of H. pylori for clarithromycin in this northern portuguese pediatric center. This factor should determine a change in local current treatment, contraindicating the use of clarithromycin as a first-line treatment for H. pylori infection in children. The high eradication rate maybe explained for the eradication treatment tailored according antimicrobial susceptibility.
幽门螺杆菌(H. pylori)抗生素耐药性的患病率不断增加,主要是克拉霉素的耐药性降低了治疗的成功率。本研究旨在确定一线抗生素耐药性和根除率的本地模式。
对 2013 年 1 月至 2017 年 10 月期间在北母婴中心接受治疗的 H. pylori 感染患者(组织学或培养阳性检查)进行前瞻性队列研究。采用 E 试验(表型耐药性)分析 4 种抗生素的敏感性:阿莫西林、甲硝唑、克拉霉素和左氧氟沙星。选择 E 试验是因为它简单且具有成本效益,适用于常规药敏试验。还调查了赋予克拉霉素耐药性的点突变(基因型耐药性)。H. pylori 感染的根除定义为治疗结束后 6-8 周尿素呼气试验或粪便抗原阴性。
在总共 74 例 H. pylori 感染患者中,有 16 例因先前的 H. pylori 治疗或严重全身性疾病而被排除在外。感染病例的中位年龄为 15 岁(3-17 岁)。所有患者均采用 3 种抗生素(阿莫西林和甲硝唑或克拉霉素)联合质子泵抑制剂治疗 14 天,并根据抗生素敏感性进行个体化治疗。79.5%的患者完成了治疗。甲硝唑和克拉霉素的耐药率分别为 3.3%和 23.3%。阿莫西林和左氧氟沙星无耐药性。克拉霉素的基因型耐药率为 37.2%。根除率为 97.8%。
作者在葡萄牙北部的这家儿科中心发现了 H. pylori 对克拉霉素的高耐药率。这一因素应决定当地当前治疗方案的改变,克拉霉素不应作为儿童 H. pylori 感染的一线治疗药物。高根除率可能是由于根据抗生素敏感性进行个体化治疗的结果。